A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Trial Profile

A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2015

At a glance

  • Drugs Etirinotecan pegol (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 25 Nov 2014 Planned End Date changed from 1 Jul 2014 to 1 nov 2015 as reported by ClinicalTrials.gov.
    • 25 Nov 2014 Planned primary completion date changed from 1 Jul 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top